Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixivaptan in ADPKD Patients with Prior Tolvaptan Intolerance
NCT04152837Phase 3Terminated
- Sponsor
- Palladio Biosciences
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Palladio Biosciences. Started Sep 2020; status: terminated.
02
Drugs
lixivaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04152837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152837.